Envoy Medical (COCH)
NASDAQ:COCH
Want to see COCH full AI Analyst Report?
Top Page
Envoy Medical
(NASDAQ:COCH)
Select Model
Select Model
Rating:49Neutral
Price Target:
$0.63
▼(-8.55% Downside)
Action:ReiteratedDate:03/23/26
The score is held down primarily by very weak financial performance (negative gross profit, severe losses, and heavy cash burn alongside negative equity). Technicals have improved in the short term and corporate events reduced immediate financing and delisting risk, but losses and dilution risk remain the dominant constraints.
Positive Factors
Addressable market and implanted platform
Envoy’s fully implanted Acclaim platform targets sensorineural hearing loss, a multi‑billion‑dollar structural market. A durable platform can drive surgeon adoption, recurring device-related services and upgrades, and long-term revenue streams if clinical/regulatory milestones are achieved.
Negative Factors
Sustained heavy cash burn
Persistent ~-$18M annual cash burn creates structural dependence on external capital and elevates dilution and financing risk. Until operations generate positive operating cash flow, management must secure funding to complete trials and commercial launch, limiting long‑term self‑sufficiency.
Read all positive and negative factors
Positive Factors
Negative Factors
Addressable market and implanted platform
Envoy’s fully implanted Acclaim platform targets sensorineural hearing loss, a multi‑billion‑dollar structural market. A durable platform can drive surgeon adoption, recurring device-related services and upgrades, and long-term revenue streams if clinical/regulatory milestones are achieved.
Read all positive factors
Envoy Medical (COCH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$52.28M
Dividend YieldN/A
Average Volume (3M)394.38K
Price to Earnings (P/E)―
Beta (1Y)0.21
Revenue Growth7.11%
EPS Growth6.53%
CountryUS
Employees42
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.29
Shares Outstanding76,881,110
10 Day Avg. Volume193,663
30 Day Avg. Volume394,378
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-1.10
Price to Sales (P/S)53.77
P/FCF Ratio-0.70
Enterprise Value/Market Cap0.22
Enterprise Value/Revenue46.71
Enterprise Value/Gross Profit-17.78
Enterprise Value/Ebitda-0.51
Forecast
1Y Price Target
$2.50Price Target Upside262.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.95
Revenue Forecast (FY)$200.00K
Envoy Medical Business Overview & Revenue Model
Company Description
Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include hearing aids; Esteem middle ear implants; bone conduction devices; and Acclaim cochlear implants. Envoy Medical Corpor...
How the Company Makes Money
Envoy Medical’s primary path to monetization is selling its hearing devices and related components through the hearing healthcare ecosystem. In practice, this typically includes (1) revenue from product sales of implantable hearing systems and ass...
Envoy Medical Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
8
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 241.00K | 225.00K | 316.00K | 237.00K | 310.00K |
| Gross Profit | -633.00K | -517.00K | -473.00K | -261.00K | -459.00K |
| EBITDA | -21.97M | -19.81M | -29.79M | -8.63M | -6.80M |
| Net Income | -23.76M | -20.80M | -29.92M | -15.92M | -8.68M |
Balance Sheet | |||||
| Total Assets | 8.56M | 11.54M | 8.27M | 2.56M | 2.62M |
| Cash, Cash Equivalents and Short-Term Investments | 3.74M | 5.48M | 4.22M | 183.00K | 1.12M |
| Total Debt | 919.00K | 19.66M | 562.00K | 34.53M | 23.48M |
| Total Liabilities | 20.32M | 30.38M | 10.05M | 38.75M | 47.58M |
| Stockholders Equity | -11.77M | -18.84M | -1.78M | -36.20M | -44.96M |
Cash Flow | |||||
| Free Cash Flow | -18.38M | -18.93M | -17.24M | -9.02M | -7.06M |
| Operating Cash Flow | -18.20M | -17.95M | -17.09M | -8.80M | -6.94M |
| Investing Cash Flow | -179.00K | -980.00K | -153.00K | -218.00K | -125.00K |
| Financing Cash Flow | 16.63M | 20.20M | 21.28M | 8.09M | 8.06M |
Envoy Medical Technical Analysis
Positive
0.69
Price Trends
0.69
Positive
0.70
Positive
0.93
Negative
Market Momentum
>-0.01
Negative
52.06
Neutral
73.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COCH, the sentiment is Positive. The current price of 0.69 is above the 20-day moving average (MA) of 0.69, above the 50-day MA of 0.69, and below the 200-day MA of 0.93, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.06 is Neutral, neither overbought nor oversold. The STOCH value of 73.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for COCH.
Envoy Medical Risk Analysis
Envoy Medical disclosed 46 risk factors in its most recent earnings report. Envoy Medical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Envoy Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $124.44M | -4.20 | -111.74% | ― | ― | ― | |
49 Neutral | $52.28M | -0.55 | 129.49% | ― | 7.11% | 6.53% | |
49 Neutral | $20.00M | -1.58 | -312.04% | ― | -100.00% | 92.41% | |
46 Neutral | $39.71M | -6.64 | -119.92% | ― | -0.38% | 37.91% | |
44 Neutral | $10.79M | -0.68 | -335.47% | ― | 16.05% | 27.95% |
* Healthcare Sector Average
COCH
Envoy Medical
0.68
-0.67
-49.56%
EDAP
EDAP TMS
3.47
1.25
56.38%
MODD
Modular Medical
4.14
-27.06
-86.73%
NMTC
NeuroOne Medical Technologies
4.35
0.60
15.91%
VVOS
Vivos Therapeutics
0.81
-1.92
-70.44%
ADGM
Adagio Medical Holdings
1.03
-0.23
-18.25%
Envoy Medical Corporate Events
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Envoy Medical Regains Nasdaq Listing Compliance After Financing
Positive
Feb 27, 2026
On February 24, 2026, Envoy Medical announced it had regained compliance with Nasdaq’s continued listing standards, confirming it now meets the market value requirements under Listing Rule 5550(b). The move follows a February 25, 2025 notice...
Business Operations and StrategyPrivate Placements and Financing
Envoy Medical Closes Upsized Public Offering to Fund Growth
Positive
Feb 13, 2026
On February 12, 2026, Envoy Medical announced the closing of an upsized public offering of 75 million shares of Class A common stock or pre‑funded warrants, plus Series A‑1 and Series A‑2 common warrants covering up to 120 millio...
Executive/Board Changes
Envoy Medical Grants Stock Options to Key Executives
Positive
Feb 11, 2026
On February 5, 2026, Envoy Medical, Inc.’s compensation committee approved stock option grants for Chief Executive Officer Brent Lucas and Interim Chief Financial Officer Robert Potashnick under the company’s 2023 Equity Incentive Plan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.